NCT03743376已完成2 期
The HIV Functional Cure Potential of UB-421: A Phase II, Randomized, Open-label, Controlled, 48 Week, Proof of Concept Study, to Evaluate the Safety of UB-421 in Combination With Standard Antiretroviral Therapy (ART) and the Efficacy of HIV Reservoir Reduction as Compared With ART Alone in ART Stabilized HIV-1 Patients
United BioPharma4 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2018年12月12日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 31
- 试验地点
- 4
- 主要终点
- treatment related TEAEs
研究概览
简要总结
This study evaluate the safety of UB-421 in combination with standard antiretroviral therapy (ART) and the efficacy of HIV reservoir reduction as compared with ART alone in ART stabilized HIV-1 patients
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 100 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 sero-positive
- •Male with body weight ≥ 50 kg or female with body weight ≥ 45 kg.
- •HIV-1 plasma RNA level below 50 RNA copies/mL .
排除标准
- •Subjects with active systemic infections, except for HIV-1, that the Investigator feels the infections may confound evaluation and treatment for HIV-
- •Current active hepatitis B carriers, ie, hepatitis B surface antigen positive.
- •Current active hepatitis C carriers, ie, hepatitis C virus (HCV) antibody positive.
- •History of anaphylaxis to other mAbs.
- •Any vaccination within 8 weeks prior to the first dose of assigned drug.
- •Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior to the first dose of assigned drug.
- •Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study.
结局指标
主要结局
treatment related TEAEs
时间窗: 48Weeks
the incidence of Grade 3 drug-related treatment-emergent adverse events
次要结局
- the change of immune profiles(16Weeks)
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
2 期
The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 PatientsHIV-1-infectionNCT04404049UBP Greater China (Shanghai) Co., Ltd39
尚未招募
1 期
Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected AdultsHIV-1-infectionNCT04620291United BioPharma18
已完成
3 期
A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected PatientsHIV InfectionsNCT00002195Glaxo Wellcome290
已完成
2 期
Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected AdultsHIV-1 Infection in AdultsNCT01668043United Biomedical29
已完成
不适用
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV DrugsHIV InfectionsNCT00002217Glaxo Wellcome